# Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

> **NIH NIH R44** · RECURSION PHARMACEUTICALS, LLC · 2020 · $447,905

## Abstract

DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The platform consists of high content fluorescent image analysis using machine-learning algorithms to identify relevant and on-target changes induced in human cells in which diseases and treatments have been modeled. This system has been adapted to screen for drugs which may preferentially destroy senescent cells, as this may result in improved tissue function and decreases in pathology and mortality related to aging. In this SBIR fast-track proposal we will:  PHASE I Identify a morphological profile of senescence in a variety of human cell types. Progression to Phase II will depend on our ability to demonstrate the power of our morphological approach to identify senescent cells independent of any known senescent markers.  PHASE II Identify known drugs which preferentially destroy senescent cells, without affecting healthy cells, as identified by morphometric means.  Evaluate the efficacy of identified senolytic agents in a variety of tissue function and health-span models in mice. *Evaluate the effect of identified senolytic agents in a murine model of age-associated cardiovascular disease. Recursion Pharmaceuticals has the experience, tools, and drive to execute this Phase I/Phase II Fast-track SBIR proposal, and to accelerate commercial development of any compounds we identify as a result.

## Key facts

- **NIH application ID:** 9948564
- **Project number:** 5R44AG053131-04
- **Recipient organization:** RECURSION PHARMACEUTICALS, LLC
- **Principal Investigator:** Anthony John Donato
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $447,905
- **Award type:** 5
- **Project period:** 2016-09-15 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9948564

## Citation

> US National Institutes of Health, RePORTER application 9948564, Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction (5R44AG053131-04). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9948564. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*